

In the Claims

1-15 (Canceled).

16. (New) A composition comprising an anti-NCR antibody and a cytokine, in association with a pharmaceutically acceptable carrier, said antibody(ies) and cytokine(s) being administered together or separately to a subject in an amount effective to stimulate the proliferation of NK cells.

17. (New) The composition of claim 16, wherein said cytokine is an interleukin.

18. (New) The composition of claim 17, wherein said interleukin is selected from the group consisting of IL2, IL12, IL15, IL21 and combinations thereof.

19. (New) The composition of claim 16, wherein said antibody(ies) is an anti-NKp30 antibody or anti-NKp46 antibody, a combination of both anti-NKp30 antibody and anti-NKp46 antibody, or immunoreactive fragments thereof.

20. (New) The composition of claim 19, wherein said antibody or antibodies are used in admixture with IL2.

21. (New) The composition of claim 19, wherein said anti-NKp30 antibodies are isolated antibodies or antigen binding fragments thereof which specifically bind to a polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or an immunogenic fragment thereof, and SEQ ID NO: 5.

22. (New) The composition of claim 21, wherein said antibodies specifically bind to polypeptide comprising SEQ ID NO: 1.

23. (New) The composition of claim 19, wherein said anti-NKp30 antibodies, anti-NKp46 antibodies or combinations thereof are monoclonal antibodies, affinity, chimerized, humanized antibodies or antibodies of human origin.

24. (New) The composition of claim 23, wherein said anti-NKp30 monoclonal antibody is produced by hybridoma strain 1-2576.

25. (New) The composition of claim 16, wherein said NCR antibodies comprise antibody fragments, said fragments being essentially Fab, F(ab')₂, and Fv fragments and CDR grafted humanized monoclonal antibodies.

26. (New) The composition of claim 1, wherein said composition is in the form of tablet, powder, pastes, patches, granules, microgranules, nanoparticles, colloid solution, aqueous solution, injectable solutions, sprays, or liposomes.

27. (New) The composition of claim 1, comprising from 1 ng to 100mg/kg (body weight) of antibodies, and lower than 1 million units/square meters/day of cytokine(s).

28. (New) A method for stimulating the proliferation of NK cells which comprises contacting NK cells with an effective amount of a pharmaceutical composition according to claim 16.

29. (New) The method of claim 28, wherein one or several injections of an effective amount of said composition occurs for 5-10 days and said cytokine(s) being first injected on the same day as the first injection of antibodies.

30. (New) The method of claim 29, comprising one or two injections/day of cytokine(s) by subcutaneous injection.

31. (New) The method of claim 28, wherein said interleukin is IL-2 and is injected subcutaneously at daily doses below 1 million units/m² for 5 to 10 days.